【レポートの概要（一部）】
1. Report Overview
1.1 Global Asthma and COPD Therapies Market Overview
1.2 Global Asthma and COPD Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Asthma and COPD Therapies
2.1 The Pharmaceutical Industry: A Very Brief Overview
2.2 Classifying Respiratory Diseases: Obstructive and Restrictive
2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
2.3 What is Asthma?
2.3.1 Trends in Asthma Prevalence
2.3.2 Pathophysiology of Asthma
2.3.3 Symptoms of Asthma
2.3.4 Causes and Triggers for Asthma
2.3.5 Treatment of Asthma
2.3.6 Guidelines for Asthma Treatment
2.3.7 Drug Treatments for Asthma
2.3.8 Drug Delivery Methods in Asthma
2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 Trends in COPD Prevalence
2.4.2 Pathophysiology of COPD
2.4.3 Signs and Symptoms of COPD
2.4.4 Treatment of COPD
2.4.5 Drug Treatments for COPD
2.4.6 Guidelines for COPD Treatment
2.5 Major Drug Classes in the Treatment of Asthma and COPD
2.5.1 Bronchodilators
2.5.1.1 Beta2-Agonists
2.5.1.2 Anticholinergics
2.5.2 Anti-Inflammatory Drugs
2.5.2.1 Corticosteroids
2.5.2.2 Leukotriene Receptor Antagonists
2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.5.3 Combination Drugs
2.6 Phases of Clinical Trials
2.7 Scope of this Report
2.8 Currency Exchange Rates in This Report
3. Asthma and COPD Therapies: Global Market 2016-2026
3.1 The Global Respiratory Drugs Market by Therapeutic Area
3.2 The Global Asthma and COPD Therapies Market in 2016
3.2.1 Leading Asthma and COPD Therapies
3.2.2 Leading Companies in the Asthma and COPD Therapies Market
3.3 Global Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2016-2026
3.3.1 Global Asthma Therapies Market: Sales Forecast, 2016-2026
3.3.2 Global COPD Therapies Market: Sales Forecast 2016-2026
3.4 Global Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2016-2026
3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
3.6 How Will Segmental Shares Change to 2026
3.6.1 Global Asthma and COPD Therapies Market: Drivers and Restraints 2016-2026
3.7 Asthma and COPD Therapies: Trends and Developments
3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
4. Bronchodilator Monotherapy Market 2016-2026
4.1 Introduction to Bronchodilator Monotherapy
4.2 The Bronchodilator Monotherapy Market in 2015
4.2.1 Leading Bronchodilators in 2015
4.2.2 Bronchodilator Monotherapy: Market Forecast 2016-2026
4.2.3 How Will Market Shares by Drug Class Change to 2026?
4.3 The Anticholinergics Market 2016-2026
4.3.1 Leading Anticholinergics in 2015
4.3.2 Anticholinergics: Market Forecast 2016-2026
4.3.3 Market Share of Leading Anticholinergics to 2026
4.3.4 Spiriva (tiotropium. Boehringer Ingelheim)
4.3.4.1 Spiriva: Sales Forecast 2016-2026
4.3.4.2 Spiriva: Recent Developments
4.3.5 Atrovent (ipratropium, Boehringer Ingelheim)
4.3.5.1 Atrovent: Sales Forecast 2016-2026
4.3.6 Eklira/Tudorza/Bretaris (alcidinium, AstraZeneca/Menarini)
4.3.6.1 Eklira/Tudorza/Bretaris: Sales Forecast 2016-2026
4.4 The SABAs Market 2016-2016
4.4.1 Leading SABAs in 2015
4.4.2 SABAs: Market Forecast 2016-2026
4.4.3 Market Share of Leading SABAs to 2026
4.4.4 Ventolin (salbutamol, GSK)
4.4.4.1 Ventolin: Sales Forecast 2016-2026
4.4.5 ProAir (salbutamol, Teva)
4.4.5.1 ProAir: Sales Forecast 2016-2026
4.4.6 Proventil (salbutamol, Merck)
4.4.6.1 Proventil: Sales Forecast 2016-2026
4.4.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
4.4.7.1 Xopenex: Sales Forecast 2016-2026
4.5 The Long-Acting Beta2-Agonist (LABA) Market 2016-2026
4.5.1 Leading LABAs in 2015
4.5.2 LABAs: Market Forecast 2016-2026
4.5.3 Market Share of Leading LABAs to 2026
4.5.4 Foradil (formoterol, Merck/Novartis
4.5.4.1 Foradil: Sales Forecast 2016-2026
4.5.5 Brovana (arfomoterol, Dainippon Sumitomo)
4.5.5.1 Brovana: Sales Forecast 2016-2026
4.5.6 Arcapta/Onbrez (indacaterol, Novartis)
4.5.6.1 Arcapta/Onbrez: Sales Forecast 2016-2026
4.5.7 Severent (salmeterol, GSK)
4.5.7.1 Serevent: Sales Forecast 2016-2026
5. Anti-inflammatory Drugs Market 2016-2026
5.1 Introduction to Anti-Inflammatory Drugs
5.2 The Anti-Inflammatory Drugs Market in 2015
5.2.1 Leading Anti-Inflammatory Drugs in 2015
5.2.2 Anti-Inflammatory Drugs: Market Forecast 2016-2026
5.2.3 How Will Market Shares by Drug Class Change to 2026?
5.3 The Corticosteroids Market 2016-2026
5.3.1 Leading Corticosteroids in 2015
5.3.2 Corticosteroids: Market Forecast 2016-2026
5.3.3 Market Share of Leading Corticosteroids to 2026
5.3.4 Flixotide/Flovent (fluticasone propionate, GSK)
5.3.4.1 Flixotide/Flovent: Sales Forecast 2016-2026
5.3.5 Pulmicort (budesonide, AstraZeneca)
5.3.5.1 Pulmicort: Sales Forecast 2016-2026
5.3.6 QVAR (beclometasone, Teva)
5.3.6.1 QVAR: Sales Forecast 2016-2026
5.3.7 Asmanex (mometasone, Merck)
5.3.7.1 Asmanex: Sales Forecast 2016-2026
5.4 The Anti-Leukotrienes Market 2016-2026
5.4.1 Leading Anti-Leukotrienes in 2015
5.4.2 Anti-Leukotrienes: Market Forecast 2016-2026
5.4.3 Market Share of Leading Anti-Leukotrienes to 2026
5.4.4 Singulair (montelukast, Merck)
5.4.4.1 Singulair: Sales Forecast 2016-2026
5.5 The Monoclonal Antibodies Market 2016-2026
5.5.1 Monoclonal Antibodies: Market Forecast 2016-2026
5.5.2 Market Share of Leading Monoclonal Antibodies to 2026
5.5.3 Xolair (omalizumab, Novartis/Roche)
5.5.3.1 Xolair: Sales Forecast 2016-2026
5.5.4 Cinquil (reslizumab, Teva)
5.5.4.1 Cinquil: Sales Forecast 2016-2026
5.5.5 Nucala (Mepolizumab, GSK)
5.5.5.1 Nucala: Sales Forecast 2016-2026
5.5.6 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
5.5.6.1 Benralizumab: Sales Forecast 2016-2026
5.5.7 Lebrikizumab (RG3637, Roche)
5.5.7.1 Lebrikizumab: Sales Forecast 2016-2026
5.5.8 Dupilumab (REGN668, Regeneron/Sanofi)
5.5.8.1 Dupilumab: Sales Forecast 2016-2026
6. Combination Drugs Market 2016-2026
6.1 Introduction to Combination Drugs
6.1.1 Leading Combination Drugs in 2015
6.1.2 Combination Drugs: Market Forecast 2016-2026
6.1.3 How Will Market Shares by Drug Change to 2026?
6.1.4 Advair/Seretide (fluticasone/salmeterol, GSK)
6.1.4.1 Advair/Seretide: Sales Forecast 2016-2026
6.1.5 Symbicort (budesonide/formoterol fumarate, AstraZeneca)
6.1.5.1 Symbicort: Sales Forecast 2016-2026
6.1.5.2 Symbicort: The SMART Concept
6.1.6 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
6.1.6.1 Combivent: Sales Forecast 2016-2026
6.1.7 Dulera (formoterol/mometasone, Merck)
6.1.7.1 Dulera: Sales Forecast 2016-2026
6.1.8 Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK)
6.1.8.1 Breo/Relvar: Sales Forecast 2016-2026
6.2 Recently Launched Combination Drugs
7. Leading National Markets 2016-2026
7.1 Regional Breakdown of the Global Asthma and COPD Therapies Market
7.2 Global Asthma and COPD Therapies Market; Regional Forecasts 2016-2026
7.2.1 How Will Regional Market Shares Change to 2026?
7.2.2 National Breakdown of the Global asthma and COPD Therapies Market
7.2.3 Global Asthma and COPD Therapies Market: National Markets Forecast 2016-2026
7.2.4 How Will National Market Shares Change to 2026?
7.3 The US Asthma and COPD Therapies Market 2016-2026
7.3.1 The US Asthma and COPD Therapies Market Forecast 2016-2026
7.3.2 US Asthma and COPD Therapies Market Trends and Developments
7.3.2.1 Increasing COPD Prevalence in the US
7.3.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
7.3.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
7.4 Japanese Asthma and COPD Therapies Market 2016-2026
7.4.1 Japanese Asthma and COPD Therapies Market Forecast 2016-2026
7.4.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
7.4.2.1 Is Generic Penetration to Reach 60% by 2018?
7.4.2.2 Japanese Pharmaceutical Industry Regulatory Reform
7.5 EU5 Asthma and COPD Therapies Market 2016-2026
7.5.1 German Asthma and COPD Therapies Market Forecast 2016-2026
7.5.2 French Asthma and COPD Therapies Market Forecast 2016-2026
7.5.3 UK Asthma and COPD Therapies Market Forecast 2016-2026
7.5.4 Italian Asthma and COPD Therapies Market Forecast 2016-2026
7.5.5 Spanish Asthma and COPD Therapies Market Forecast 2016-2026
7.5.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
7.5.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
7.5.6.2 France: Social Security Finance Bill 2015
7.5.6.3 UK: Improving Asthma and COPD Patient Outcomes
7.5.6.4 Italy: Austerity Measures Limiting Growth
7.5.6.5 Spain: The Start of Recovery in the Spanish Economy
7.6 BRIC Asthma and COPD Therapies Market 2016-2026
7.6.1 Chinese Asthma and COPD Therapies Market Forecast 2016-2026
7.6.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
7.6.2.1 China’s Industrial Future and Asthma/COPD
7.6.2.2 Expansion of Healthcare Coverage and Reimbursement
7.6.2.3 Price Controls and the Anhui Model
7.6.3 Brazilian Asthma and COPD Therapies Market Forecast 2016-2026
7.6.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
7.6.4.1 Increasing Access to Medicines
7.6.5 Indian Asthma and COPD Therapies Market Forecast 2016-2026
7.6.6 Indian Asthma and COPD Therapies Market: Trends and Developments
7.6.6.1 Drug Prices Control Order 2013
7.6.6.2 Expansion of Healthcare Provision
7.6.7 Russian Asthma and COPD Therapies Market Forecast 2016-2026
7.6.8 Russian Asthma and COPD Therapies Market: Trends and Developments
7.6.8.1 No Embargo on Foreign Drug Imports
7.6.8.2 Pharma2020 and the Russian Pharmaceutical Industry
7.7 Mexican Asthma and COPD Therapies Market 2016-2026
7.7.1 Mexican Asthma and COPD Therapies Market Forecast 2016-2026
7.7.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
7.7.2.1 Seguro Popular: Mexican Healthcare Reform
7.7.2.2 COFEPRIS: Regulatory Changes and Improvements
7.7.2.3 Mexico’s Agreement for Innovation
8. Leading Companies in the Asthma and COPD Therapies Market
8.1 Asthma and COPD Therapies: Increasing Competition
8.2 Leading Companies in Asthma and COPD in 2015
8.3 Leading Companies: Market Forecast 2016-2026
8.4 How Will Leading Companies’ Market Shares Change to 2026?
8.5 GSK
8.5.1 GSK: Asthma and COPD Therapies
8.5.2 GSK: Sales Forecast 2016-2026
8.5.3 GSK: Products in Development
8.5.4 GSK: Recent Developments
8.5.4.1 Recently Launched Combination Drugs
8.5.4.2 GSK Divests OTC Products
8.5.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health
8.5.4.4 GSK Presents Data on Eosinophil Levels and COPD
8.6 Boehringer Ingelheim
8.6.1 Boehringer Ingelheim: Asthma and COPD Therapies
8.6.2 Boehringer Ingelheim: Sales Forecast 2016-2026
8.6.3 Boehringer Ingelheim: Asthma and COPD Product Development Ceased
8.6.4 Boehringer Ingelheim: Recent Developments
8.6.4.1 Expansion of Respimat Manufacturing Capacity
8.6.4.2 Respimat Safety Concerns and the TIOSPIR Study
8.6.4.3 Ben Venue Laboratories Shut Down
8.6.4.4 Sale of Roxane Laboratories
8.6.4.5 Spiloto Respimat and the PHYSACTO Study
8.7 AstraZeneca
8.7.1 AstraZeneca: Asthma and COPD Therapies
8.7.2 AstraZeneca: Sales Forecast 2016-2026
8.7.3 AstraZeneca: Products in Development
8.7.4 AstraZeneca: Recent Developments
8.7.4.1 AstraZeneca Acquires Almirall’s Respiratory Portfolio
8.7.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca’s Combination Drug Pipeline
8.7.4.3 AstraZeneca Rejects Pfizer Takeover Bid
8.7.4.4 AstraZeneca Acquires Right to Actavis’ Branded Respiratory Portfolio in US and Canada
8.7.4.5 Takeda Respiratory Portfolio Acquisition
8.8 Merck & Co. (Merck)
8.8.1 Merck: Asthma and COPD Therapies
8.8.2 Merck: Sales Forecast 2016-2026
8.8.3 Merck: Products in Development
8.8.4 Merck: Recent Developments
8.8.4.1 Bayer Acquires Merck’s Consumer Health Business
8.8.4.2 FDA Rejects Singulair OTC Switch
8.8.4.3 Takeda Ended Co-Promotion of Daxas with Merck
8.9 Novartis
8.9.1 Novartis: Asthma and COPD Therapies
8.9.2 Novartis: Sales Forecast 2016-2026
8.9.3 Novartis: Products in Development
8.9.4 Novartis: Recent Developments
8.9.4.1 Novartis Restructures Following Strategic Review
8.9.4.2 Novartis Presents Data on Ultibro and Seebri
8.9.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
8.10 Roche
8.10.1 Roche: Asthma and COPD Therapies
8.10.2 Roche: Sales Forecast 2016-2026
8.10.3 Roche: Products in Development
8.11 Teva
8.11.1 Teva: Asthma and COPD Therapies
8.11.2 Teva: Sales Forecast 2016-2026
8.11.3 Teva: Products in Development
8.11.4 Teva: Recent Developments
8.11.4.1 Launch of DuoResp Spiromax
9. Asthma and COPD Therapies Pipeline Analysis 2016-2026
9.1 A Strong Asthma and COPD Pipeline
9.2 The Bronchodilators Pipeline
9.3 Bronchodilators: Phase 3 Pipeline
9.3.1 PX1439 and PX1442 (Prosonix)
9.3.2 PT001 (glycopyrronium, AstraZeneca)
9.3.3 Spiriva Respimat (tiotropium, Boehringer Ingelheim)
9.3.4 GW642444 (vilanterol, GSK)
9.3.5 KRP-AB1102 (aclidinium, Kyorin Pharmaceutical)
9.3.6 Seebri Breezhaler (glycopyrronium, Novartis/Vectura)
9.3.7 QVAR BAI (beclometasone, Teva)
9.3.8 Albuterol MDPI/Albuterol RespiClick (salbutamol, Teva)
9.4 The Anti-Inflammatory Drugs Pipeline
9.5 Anti-Inflammatory Drugs: Phase 3 Pipeline
9.5.1 PSX1001 and PSX1050 (fluticasone propionate pMDI, Prosonix)
9.5.2 Masitinib (tyrosine kinase inhibitor, AB Science)
9.5.3 Inhaled Alpha-1 Antitrypsin (Kamada/Chiesi Farmaceutici)
9.5.4 VR506 (fluticasone propionate DPI, Vectura)
9.5.5 Favolir (budesonide, Vectura)
9.6 The Combination Drugs Pipeline
9.7 Combination Drugs: Phase 3 Pipeline
9.7.1 Seriveo (fluticasone/salmeterol, Circassia) (Formerly PSX2005 (Prosonix))
9.7.2 Duaklir Genuair (LAS40464) (aclidinium/formoterol, AstraZeneca)
9.7.3 Bevespi Aerosphere (PT003) (glycopyrronium/formoterol, AstraZeneca)
9.7.4 Tiotropium/Olodaterol Fixed-Dose Combination (LAMA/LABA, Boehringer Ingelheim)
9.7.5 Easyhaler Combination Drugs (Orion)
9.7.6 VR632 (ICS/LABA, Vectura/Sandoz)
9.8 Other Asthma and COPD Drugs Pipeline
10. Qualitative Analysis of the Asthma and COPD Therapies Market 2016-2026
10.1 SWOT Analysis of the Asthma and COPD Therapies Market
10.2 Strengths
10.2.1 Increasing Prevalence and Disease Burden
10.2.2 High Costs of Treatment
10.2.3 The Changing Perception of COPD
10.2.4 Patient Education: Understanding the Severity of Respiratory Disease
10.2.5 Lifecycle Management Strategies to Counter Patent Expiry
10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion
10.2.7 Developments in Diagnostics
10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD
10.2.7.2 Biological Markers in COPD
10.3 Weaknesses
10.3.1 Under-Diagnosis: the ‘Ghost Population’
10.3.2 Side-Effects of Drug Classes
10.3.3 Patent Cliff for Devices
10.3.4 Low Patient Adherence
10.3.5 Costing Pressures in both Developed and Emerging Markets
10.4 Opportunities
10.4.1 Patient Phenotyping and Personalised Medicine
10.4.2 A Strong R&D Pipeline
10.4.3 Ultra-Long-Acting Beta2-Agonists
10.4.4 Muscarinic Antagonists and Beta2-Agonists (MABAs)
10.4.5 Monoclonal Antibodies
10.4.6 LAMA/LABA Combinations
10.4.7 Opportunities in Telehealth
10.5 Threats
10.5.1 Patent Expiry and Generic Competition
10.5.2 Pharmacy Benefit Managers and Cost Control
10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD
10.6 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market
10.6.1 Rivalry among Competitors [Medium]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Medium]
10.6.4 Power of Buyers [High]
10.6.5 Threat of Substitutes [Low]
11. Conclusions
11.1 Asthma and COPD Therapies: A Maturing Market
11.2 The Global Asthma and COPD Therapies Market in 2015
11.3 Current Leading Asthma and COPD Therapies Segments
11.3.1 Leading Asthma and COPD Therapies
11.3.2 Leading Asthma and COPD Therapies Companies
11.4 Leading Regional and National Markets
11.5 Global Asthma and COPD Therapies Market Forecast 2016-2026
11.6 The Future of the Asthma and COPD Therapies Market
11.6.1 Growth in Anti-Inflammatory and Combination Drugs
11.6.2 Personalised Medicine
11.6.3 Unmet Needs in Asthma and COPD
11.7 Strategies for Growth in 2016-2026
12. Glossary
【レポート販売概要】
■ タイトル：喘息＆COPDの世界市場2016-2026■ 英文：Asthma & COPD Market Report 2016-2026
■ 発行日：2016年10月
■ 調査会社：visiongain
■ 商品コード：VGAIN61125
■ 調査対象地域：グローバル
- リングメインユニット（RMU）の世界市場予測（～2022年）The global ring main unit market is projected to grow at a CAGR of 8.35% from 2017 to 2022, to reach a market size of USD 2.45 Billion by 2022. This growth is attributed to modernization of existing power infrastructure and huge electricity demand in developing countries. Investments for renewable power generation in Asia-Pacific countries have been planned to meet the rising power demand. These i …
- 保険業界におけるソーシャルメディアの活用The report provides top-level market analysis, information and insights into social media in the insurance industry. It provides: • A global snapshot of social media and growth opportunities for the insurance industry. • Comprehensive analysis of social media practice across insurance business functions. • Analysis of social media marketing opportunities and challenges for insurance companies. • D …
- 自動車用パワースライドドアシステムの世界市場2018-2022About Automotive Power Sliding Door System An automotive door is typically hinged, but in many cases, it can also be attached by other mechanisms, such as tracks. The doors in a vehicle can either be opened manually or can be powered electronically. Technavio’s analysts forecast the global automotive power sliding door system market to grow at a CAGR of 18.31% during the period 2018-2022. Covered …
- フランスの感染症検査市場2014This report provides an overview of the French infectious disease diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Table of ContentsBusiness EnvironmentMarket Structure Market Size, Growth, and Major Suppliers' Market SharesList of Tables &n …
- バイオ系プラットフォーム化学品の世界市場2017-2021：バイオ系1,4-二酸、バイオ系グリセリン、バイオ系グルタミン酸、バイオ系3-ヒドロキシプロピオン酸、バイオ系イタコン酸About Bio-Based Platform Chemicals Bio-based platform chemicals are compounds containing two to six carbons and are derived from renewable resources. They are used as important precursors for producing a variety of chemicals and materials, such as pharmaceuticals, perfumes, solvents, fuels, and polymers. Platform chemicals are two to six carbon-containing compounds derived from fossil fuel resourc …
- デジタル保証の世界市場展望2017-20276According to Stratistics MRC, the Global Digital Assurance market accounted for $2.66 billion in 2017 and is expected to reach $9.73 billion by 2026 growing at a CAGR of 15.5 % during the forecast period. Some of the key factors such as increasing need of API monitoring and rising use of agile and devops methodologies in SDLC are driving the market growth. However, the shadow IT is a major risk ar …
- 2014年戦略提言：日本のHIV/AIDS診断・検査市場Complete report $2,300. DataPack (test volumes, sales forecasts, supplier shares) $1,500.Summary This report presents detailed analyses of the AIDS diagnostics market in Japan. The report provides test volume and sales forecasts for HIV-1/2, HIV Ag, NAT, Western Blot and other confirmatory tests performed in the following market segments: - Hospitals …
- 産業用・バルク・輸送包装の世界市場The global industrial, bulk and transport packaging market is estimated to be worth $241.1 billion in 2015 and is projected to grow strongly to 2025. Although economies are still weak in some parts of the world, especially in the Euro area and in some emerging economies, the global economy is set to recover. Rising consumption will require more production and thus stimulate industrial activities. …
- 放射線検出、監視、および安全性の世界市場分析：製品別（個人線量計、エリア・プロセス・モニター、放射性物質モニター）、検知タイプ別、安全タイプ別、エンドユーザー別、セグメント予測、2013-2024The radiation detection, monitoring & safety market is expected to reach USD 1.6 billion by 2024, according to a new report by Grand View Research, Inc., given the contentious nature of radioactive material, employed in varied spheres including consumer products, such as fluorescent lamps and radio luminous products, and in the field of nuclear medicine, there is an urging need for caution in thei …
- 光パルス試験器（OTDR）の世界市場2019-2023About this market Increasing investments in data center to drive market growth. Data centers are networked computer servers that are used by organizations for the remote distribution, processing, and storage of large volumes of data. The development of smart cities, smart grids, and smart homes generates a large amount of data. Monitoring and processing this data have become a priority, which crea …
- 生体用接着剤の世界市場：食物ベース接着剤、動物ベース接着剤The report covers the global bioadhesive market. It divides the market on the basis of types, applications and regions. The market data for these types is given with respect to volume (Kilo Tons) and value ($Million). The market size in terms of volume of bioadhesive is projected to reach $6 billion by 2019 with a CAGR of 13.0% between 2014 and 2019. The data mentioned in the report is based on th …
- 種実類の世界市場2016-2020About Nuts and Seeds Nuts and seeds emerged as the third-largest category in the overall snacks market in 2015, accounting for a market share of 15.66%. Nuts include almonds, macadamia nuts, pistachios, peanuts, walnuts, and cashews. Seeds include sesame seeds, pumpkin seeds, chia seeds, sunflower seeds, hemp seeds, and flaxseeds. Rising demand for ready-to-eat snacks and convenient foods has fuel …
- 2014年戦略提言：イタリアの治療薬物モニタリング(TDM)市場This new 247-page report from Venture Planning Group provides a comprehensive analysis of the Italian therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carb …
- グローバル鉱業の景況感レポート（2015年上半期）Summary “Mining Business Confidence Report H1 2015” is a new report by Kable that globally analyzes industry opinions on the latest economic and customer issues, and their impact on investment decisions and growth prospects within the mining industry. This report also examines executive opinions with regards to the current and future state of the economy and its effect on the industry. It analyzes …
- Semaglutide (Type 2 Diabetes)：市場予測と分析（～2022）Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 20 …
